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Abstract
Objectives
To compare drug survival in patients with axial spondyloarthritis treated with different TNF
inhibitors in standard dosage.
Methods
Patients fulfilling the Assessment in SpondyloArthritis international Society classification cri-
teria for axial spondyloarthritis in the Swiss Clinical Quality Management cohort were
included in this study if a first TNF inhibitor on standard dosage was started after recruitment
and if a baseline visit was available. Drug maintenance up to drug discontinuation or dose
escalation was compared between TNF inhibitors with multiple adjusted Cox proportional
hazards models and multiple imputation for missing baseline covariate data.
Results
A total of 966 patients were included (adalimumab 344, etanercept 237, golimumab 214,
infliximab 171). Patients on certolizumab (n = 18) were excluded. Patients starting golimu-
mab had lower disease activity as well as better physical function and quality of life in com-
parison to patients starting another drug. A higher proportion of patients starting infliximab
had a history of extra-articular manifestations. Drug dosage was more often escalated dur-
ing follow-up in patients treated with infliximab than with subcutaneously administered
agents. However, no significant differences in time up to drug discontinuation or dose esca-
lation were observed in multiple adjusted analyses if treatment was initiated after 2009,
when all 4 TNF inhibitors were available: hazard ratio for infliximab versus etanercept 1.16
(95% confidence interval 0.80; 1.67), p = 0.44, for golimumab versus etanercept 0.80 (0.58;
1.10), p = 0.17 and for adalimumab versus etanercept 0.93 (0.69; 1.26), p = 0.66.
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Conclusion
In axial spondyloarthritis, drug survival with standard doses of different TNF inhibitors is
comparable.
Introduction
Drug survival is a composite measure of effectiveness and safety. It is additionally influenced
by the number of alternative treatment options and changes in the population treated over
time. Moreover, personal preferences of patients and their physicians, governmental interven-
tions in the health care system and marketing efforts of the pharmaceutical industry may have
an impact on drug maintenance. In axial spondyloarthritis (axSpA), several national register
studies have demonstrated a better drug retention in patients treated with etanercept (ETA)
and adalimumab (ADA) in comparison to infliximab (IFX) [1–3]. In contrast, other studies in
axSpA, including our previous analyses, have suggested that the choice of the TNFi did not
affect drug survival [4–10]. These results might have been confounded by the fact that discon-
tinuation rates usually increase with later calendar periods, as alternative treatment options
arise, as demonstrated for rheumatoid arthritis [11]. Moreover, a differential immunogenicity
has been described for the different anti-TNF agents, potentially leading to a gradual loss of
effectiveness [12, 13]. We hypothesized that the failure to detect a lower drug retention in
patients with IFX in some studies might be due to a higher proportion of patients on IFX pre-
senting with an increase in dosage during follow-up. The aim of this study was to compare
drug survival up to dose escalation in axSpA patients treated with different TNFi and to adjust
for additional potential confounders not available in previous analyses.
Materials and methods
Study population
Patients with a clinical diagnosis of axSpA recruited in the SCQM cohort [14] since 2004 were
included in the current study if they fulfilled the Assessment in SpondyloArthritis interna-
tional Society (ASAS) classification criteria for axSpA [15], if they started a first TNFi approved
for this condition after recruitment on a licensed standard dosage and if baseline disease activ-
ity information was available. Clinical assessments were performed according to the recom-
mendations of ASAS [16] and visits were scheduled annually after baseline. Intermediate visits
were recommended before and 3 months after treatment changes. Scoring of sacroiliac joints
allowing for differentiation between nonradiographic axSpA (nr-axSpA) and ankylosing spon-
dylitis (AS) was performed centrally [17]. The study was approved by the Ethics Commission
of the Canton of Zurich. Written informed consent was obtained from all patients.
Drug retention analyses
Medication start and stop dates indicated by the treating rheumatologist were used to estimate
the time individual patients maintained their first TNFi treatment. With the introduction of a
smartphone application in 2016, SCQM patients can additionally report if the medication
information entered by the rheumatologist in the database is correct on a monthly basis.
Observations were censored at the last visit or at the last change in TNFi dosage registered in
SCQM, whatever occurred last. To account for potential differences in dose escalation between
different TNFi (ADA, certolizumab (CER), ETA, golimumab (GOL) and IFX, time to drug
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discontinuation or dose escalation (referred to as time to dose escalation/stop) was additionally
analyzed. Dose escalation of TNFi was defined as either an increase in dose or a shortening of
the interval between treatment administrations of>10%.
Statistical analysis
Baseline characteristics between patients treated with different anti-TNF agents were com-
pared using the Fisher’s exact test for categorical variables and the Mann-Whitney test for con-
tinuous variables. Crude time to treatment discontinuation as well as time to dose escalation/
stop were described with Kaplan-Meier plots. Log-rank test p-values are provided. Multiple
adjusted Cox proportional hazards models were set up to estimate a covariate-adjusted effect
of the choice of TNFi on drug maintenance. The following baseline covariates were consid-
ered: sex, age, disease duration, calendar period (to account for the number of TNFi at choice
at different time-points during follow-up), human leucocyte antigen (HLA) B27, classification
status as nr-axSpA vs. AS, co-medication with conventional synthetic anti-rheumatic disease-
modifying drugs (csDMARDs), Bath Ankylosing Disease Activity Index (BASDAI), Bath
Ankylosing Disease Functional Index (BASFI), elevated C-reactive protein (CRP) status, pres-
ence of extra-articular manifestations, current smoking, education (either vocational or uni-
versity education versus compulsory education), body mass index (BMI�30 and>25 versus
normal weight, respectively), physical exercise (yes versus no) and interactions between calen-
dar period and TNFi type. To avoid collinearity between selected covariates, adjustment was
finally performed for sex, disease duration, classification status, BASDAI, csDMARD co-medi-
cation, elevated CRP status, presence of extra-articular manifestations, current smoking, edu-
cation, calendar period and its interaction with the type of TNFi.
The cox models were fitted using multiple imputation of missing covariate data to account
for missing values [18]. Out of 873 treatments, 598 had at least one missing value in one of the
11 variables used. The proportion of missing values per variable varied from 0% to 39% (the
latter pertaining to classification status as nr-axSpA versus AS, when a conventional radio-
graph of the pelvis was not available).
R statistical software (R Development Core Team, 2011) was used for all analyses. All tests
were two-sided, with the significance level set to 0.05.
Results
Baseline characteristics
A total of 984 patients started a first TNFi with standard dosage after inclusion into the cohort
and had a baseline visit. CER was initiated as a first TNFi in only 18 patients and excluded
from the analyses. Baseline characteristics of the remaining 966 patients treated with different
anti-TNF agents are shown in Table 1 (ADA n = 344, ETA n = 237, GOL n = 214, IFX
n = 171). Corresponding to the different time-points of their approval for AS (and later axSpA
for some TNFi), the median year of treatment initiation differed between the individual drugs.
Patients treated with GOL, a biologic first approved for this indication in Switzerland in 2010,
had a lower disease activity as well as a better function, spinal mobility and health-related qual-
ity of life at baseline. No significant differences were observed for sex, HLA-B27 positivity, age
at disease onset, presence of peripheral arthritis or enthesitis between the individual TNFi. The
presence of extra-articular manifestations in patient history affected the choice of the first
TNFi: Only 4.2% of patients with inflammatory bowel disease were treated with ETA, while
the respective proportion of patients treated with IFX was 18.6% (p<0.001). IFX was most fre-
quently used in combination with csDMARDs (17.0% vs. 13.9% in ADA, 11.8% in ETA and
7.5% in GOL; overall p = 0.03).
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Dose escalation during follow-up
The proportion of patients with dose escalation was analyzed during the observation time
in SCQM, excluding patients having experienced both a reduction and an increase in dosage
during follow-up (n = 11). It was significantly higher in patients treated with IFX in contrast
to TNFi administered subcutaneously (IFX 18% vs. ADA 2%, ETA 0%, GOL 1%; overall
p-value <0.001).
Drug maintenance
Treatment retention analysis was performed in 873 patients, as 93 patients had no database
entries after the baseline visit and were therefore censored at treatment start. Baseline charac-
teristics of this large subgroup of patients were comparable to the whole population (Table 2).
The TNFi was discontinued in 493 patients during follow-up. The reasons for treatment dis-
continuation are provided in Table 2.
Table 1. Baseline characteristics at start and reasons for later discontinuation of first TNF inhibitor.
Parameter N ADA
N = 344
ETA
N = 237
GOL
N = 214
IFX
N = 171
Overall
P value
Year TNFi start
median, IQR
966 2010
2009;2013
2009
2006;2013
2014
2012;2016
2010
2007; 2012
<0.001
Male sex, % 966 54.1 57.4 54.7 63.2 0.23
AS, % 572 65.9 78.3 62.8 75.2 0.01
Age, years 966 38.9 (11.4) 39.2 (10.5) 38.4 (12.2) 40.2 (11.6) 0.34
Age at first symptoms 966 26.8 (8.3) 26.9 (8.3) 27.2 (8.4) 27.6 (9.1) 0.86
Symptom duration, years 954 12.2 (11.0) 12.3 (9.9) 11.2 (11.4) 12.5 (10.5) 0.11
HLA-B27 pos, % 892 73.9 75.9 79.2 76.1 0.58
BASDAI 795 5.6 (2.0) 5.7 (2.0) 5.3 (2.0) 5.8 (1.8) 0.15
Patient GA 798 6.4 (2.3) 6.7 (2.4) 6.1 (2.3) 6.4 (2.4) 0.08
ASDAS-CRP 746 3.4 (0.9) 3.5 (0.9) 3.2 (0.9) 3.5 (0.9) 0.002
Elevated CRP, % 897 48.1 50.5 45.1 54.2 0.36
BASFI 801 4.0 (2.6) 4.3 (2.4) 3.4 (2.3) 4.5 (2.4) <0.001
BASMI 817 1.9 (1.9) 2.2 (1.9) 1.7 (1.6) 2.4 (2.0) 0.01
EQ-5D 785 54.4 (21.5) 53.1 (22.6) 60.4 (20.0) 54.0 (21.6) 0.01
Arthritis, % 938 35.4 36.4 34.3 32.9 0.90
Enthesitis, % 937 74.2 73.0 69.5 68.3 0.43
EAM ever, % 802 37.9 38.8 28.0 52.5 <0.001
Uveitis ever, % 865 19.5 20.6 13.9 26.8 0.03
Psoriasis ever, % 771 10.4 13.4 12.2 12.1 0.79
IBD ever, % 857 11.4 4.2 5.8 18.6 <0.001
csDMARD at BL, % 966 13.9 11.8 7.5 17.0 0.03
• methotrexate, % 966 7.8 4.2 3.7 8.2 0.08
• sulfasalazine, % 966 7.3 5.9 3.7 8.2 0.24
• leflunomide, % 966 0.0 1.3 0.5 2.3 0.02
Current smokers, % 765 37.8 31.4 36.8 42.9 0.18
Except where indicated otherwise, values are the mean (standard deviation). ADA = Adalimumab; AS = Ankylosing Spondylitis; ASDAS-CRP = Ankylosing Spondylitis
Disease Activity Score using C-reactive protein (CRP) levels; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis
Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; BL = baseline; csDMARD = conventional synthetic Disease-Modifying Anti-Rheumatic
Drug; EAM = Extra-articular manifestations; EQ-5D = EuroQoL-5domains; ETA = Etanercept; GA = Global assessment; GOL = Golimumab; HLA-B27 = human
leucocyte antigen B27; IBD = Inflammatory bowel disease; IFX = Infliximab; TNF = Tumor Necrosis Factor.
https://doi.org/10.1371/journal.pone.0216746.t001
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Drug survival is shown for individual TNFi during the whole follow-up in SCQM (2004–
2018) in Fig 1A (overall log-rank test p-value 0.23). Binary differences were similarly statisti-
cally not significant (ETA-GOL p = 0.45, ETA-IFX p = 0.49, ETA-ADA 0.09, GOL-IFX
p = 0.82, GOL-ADA p = 0.59, ADA-IFX p = 0.42). Drug retention is also depicted for individ-
ual TNFi after stratification for periods of time corresponding to the number of TNFi available
as treatment options (2 TNFi during 2004–2005; 3 TNFi during 2006–2009; at least 4 TNFi
2010–2018, Fig 1B–1D, respectively).
Table 2. Baseline characteristics at start of first TNF inhibitor of patients retained in the drug retention analysis.
Baseline
characteristics
N ADA
N = 320
ETA
N = 216
GOL
N = 183
IFX
N = 154
P
Year TNFi start
median, IQR
873 2011
(2008; 2013)
2008
(2006; 2012)
2014
2012; 2015)
2009
(2007; 2012)
<0.001
Male sex, % 873 54.1 58.3 56.3 66.9 0.06
AS, % 535 64.7 79.9 64.3 76.0 0.008
Age, years 873 39.2 (11.5) 39.0 (10.4) 38.7 (12.4) 39.8 (11.3) 0.68
Age at first symptoms 864 26.9 (8.3) 26.5 (8.2) 26.7 (8.2) 27.4 (9.0) 0.69
Symptom duration, years 864 12.4 (11.1) 12.4 (9.7) 12.0 (11.7) 12.4 (9.9) 0.49
HLA-B27 pos, % 804 74.0 77.7 79.7 76.1 0.55
BASDAI 726 5.6 (2.0) 5.7 (2.0) 5.2 (2.0) 5.8 (1.8) 0.07
Patient GA 727 6.5 (2.3) 6.7 (2.5) 5.9 (2.3) 6.4 (2.4) 0.01
ASDAS-CRP 683 3.4 (0.9) 3.5 (0.9) 3.1 (0.9) 3.6 (0.9) <0.001
Elevated CRP, % 815 48.8 50.2 44.6 55.0 0.34
BASFI 730 4.0 (2.7) 4.3 (2.5) 3.3 (2.3) 4.5 (2.4) <0.001
BASMI 740 2.0 (1.9) 2.2 (1.9) 1.7 (1.7) 2.4 (2.1) 0.01
EQ-5D 714 54.3 (21.8) 52.8 (22.7) 62.0 (19.0) 53.4 (22.2) <0.001
Arthritis, % 846 35.6 35.2 34.5 30.7 0.76
Enthesitis, % 846 74.8 72.2 69.4 69.6 0.52
EAM ever, % 736 36.9 40.7 28.9 53.9 <0.001
Uveitis ever, % 792 19.4 22.6 12.6 27.7 0.007
Psoriasis ever, % 711 10.4 12.8 12.9 12.8 0.78
IBD ever, % 784 10.8 4.6 6.1 18.2 0.001
csDMARD, % 873 14.4 11.6 6.0 17.5 0.008
• methotrexate, % 873 8.1 4.2 3.8 9.1 0.07
• sulfasalazine, % 873 7.5 6.0 2.2 9.1 0.04
• leflunomide, % 873 0.0 0.9 0.6 1.9 0.04
Current smokers, % 695 38.3 32.0 37.5 42.1 0.32
Reasons of
discontinuation
493 0.01
• Ineffectiveness, % 243 54.1 48.8 47.0 42.1
• Adverse Events, % 97 17.0 15.7 19.3 30.5
• Remission, % 50 11.9 5.0 13.2 10.5
• Other, % 103 17.0 30.6 20.5 16.8
Except where indicated otherwise, values are the mean (standard deviation). ADA = adalimumab; AS = Ankylosing Spondylitis; ASDAS-CRP = Ankylosing Spondylitis
Disease Activity Score using C-reactive protein (CRP) levels; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis
Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; csDMARD = conventional synthetic Disease-Modifying Anti-Rheumatic Drug;
EAM = Extra-articular manifestations; EQ-5D = EuroQoL-5domains; ETA = etanercept; GA = Global assessment; GOL = golimumab; HLA-B27 = human leucocyte
antigen B27; IBD = Inflammatory bowel disease; IFX = infliximab; TNF = Tumor Necrosis Factor.
https://doi.org/10.1371/journal.pone.0216746.t002
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In multiple adjusted Cox regression analyses, female sex and classification as nr-axSpA
were associated with a higher hazard of discontinuation, while elevated CRP levels, vocational
versus compulsory education, as well as treatment with ETA in the calendar period before
2006 in contrast to 2006–2009 were associated with a lower hazard of treatment stop (Fig 2A).
Comedication with csDMARDs was not found to be associated with a significantly lower haz-
ard of discontinuation (HR 0.78, 95% CI 0.59; 1.03) in this analyses.
Comparable results were found for the complete case analysis (Table 3).
Paralleling the differences in the observed course of individual drug retention after stratifi-
cation for different time periods in Fig 1B–1D, a significant interaction was found between the
calendar period of treatment initiation and the type of TNFi in the adjusted analyses. To allow
for an easier interpretation of interactions, the hazard ratios (HR) of treatment discontinuation
of different TNFi within a calendar period, as well as the HR of treatment discontinuation of
each TNFi in different calendar periods were calculated from main effects and interactions in
the model. In contrast to ETA, a trend for a higher discontinuation rate was found for IFX dur-
ing the period prior to 2006 compared to the following period 2006–2009 (HR 1.84, 95% CI
0.98; 3.46, p = 0.06). A trend for a lower drug retention was detected for all three biologics
(ADA, ETA, IFX) for the treatment period after 2009, when compared to the period 2006–
2009, although differences reached statistical significance only for ADA. Pairwise comparisons
Fig 1. Kaplan-Meier curves showing drug survival of the first TNFi, stratified by the type of TNFi used. A. Treatment initiation during the whole
observation time in SCQM. B-D. Stratitication by the number of TNFi available as treatment options at the time-point of treatment initiation. B. ETA and IFX
in treatment initiation 2004–2005. C. ADA, ETA and IFX in treatment initiations 2006–2009. D. ADA, ETA, GOL and IFX in treatment initiations after 2009.
ADA = adalimumab, ETA = etanercept, GOL = golimumab, IFX = infliximab.
https://doi.org/10.1371/journal.pone.0216746.g001
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of HR of discontinuation for different monoclonal anti-TNF antibody drugs and ETA by cal-
endar periods are shown in Table 4A. IFX was discontinued more frequently than ETA before
2006, a period when only these two anti-TNF agents were available (hazard ratio (HR) 3.10,
95% confidence interval (CI) 1.52; 6.33, p = 0.002). No significant differences between the dis-
continuation rates of individual TNFi could be detected at later time-points, with 3 TNFi avail-
able after 2006, and>3 after 2009 (Tab.4A).
Drug maintenance up to dose escalation
As these results might have been confounded by the higher rate of dose escalation during fol-
low-up, mainly observed for IFX, we next analyzed drug maintenance up to dose escalation.
The results are shown as a Kaplan-Meier plot in Fig 3.
Indeed, a shorter time to dose escalation/stop was found for IFX versus ETA in this unad-
justed analysis (log-rank p value 0.01). It was, in contrast, comparable between ADA, ETA and
GOL, when compared pairwise. The multiple adjusted analysis confirmed a longer time to
Fig 2. Multivariable adjusted Cox regression models for drug survival (A) and drug survival up to dose escalation (B) in axSpA patients treated with a first
TNFi. ETA and the period after 2009 are used as references in this models. HRs>1 indicate increased hazard for discontinuation. ADA = adalimumab,
AS = ankylosing spondylitis, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, BASFI = Bath Ankylosing Spondylitis Functional Index, BMI = body
mass index, CI = confidence interval, CRP = C-reactive protein, csDMARD = conventional synthetic disease-modifying anti-rheumatic drug, ETA = etanercept,
GOL = golimumab, HLA-B27 = Human Leucocyte Antigen B27, HR = hazard ratio, IFX = infliximab, nr-axSpA = nonradiographic axial spondyloarthritis,
TNFi = Tumor Necrosis Factor inhibitor.
https://doi.org/10.1371/journal.pone.0216746.g002
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Table 3. Multivariable adjusted Cox regression models with complete case data.
A. Drug survival B. Drug survival up to dose escalation
Variable HR 95% CI P HR 95% CI P
ADA vs. ETA 0.77 0.47; 1.25 0.29 0.77 0.49; 1.23 0.28
GOL vs. ETA 0.57 0.32; 1.02 0.06 0.67 0.39; 1.15 0.15
IFX vs. ETA 0.76 0.41; 1.41 0.39 1.24 0.71; 2.15 0.45
Disease duration
(in square-root years)
1.03 0.93; 1.14 0.57 1.02 0.93; 1.11 0.71
Female sex 1.29 0.96; 1.74 0.10 1.18 0.89; 1.56 0.25
nr-axSpA vs. AS 1.30 0.92; 1.84 0.13 1.15 0.83; 1.59 0.40
Elevated CRP 0.84 0.63; 1.13 0.25 0.83 0.64; 1.10 0.19
Extra-articular manifestations 0.94 0.70 ; 1.27 0.71 0.94 0.72 ; 1.24 0.67
Current smoking 0.98 0.73 ; 1.32 0.92 1.04 0.79 ; 1.37 0.76
csDMARD comedication 0.67 0.42 ; 1.06 0.08 0.82 0.55 ; 1.22 0.33
BASDAI 1.04 0.96 ; 1.12 0.37 1.03 0.96 ; 1.10 0.47
Vocational vs compulsory education 0.75 0.51 ; 1.12 0.17 0.83 0.56 ; 1.21 0.33
University vs compulsory education 0.82 0.53 ; 1.29 0.40 0.96 0.62 ; 1.47 0.83
Calendar period before 2006 vs. 2006–2009 0.55 0.26; 1.16 0.12 0.43 0.21; 0.87 0.02
Calendar period 2006–2009 vs. after 2009 0.60 0.33 ; 1.10 0.10 0.65 0.38 ; 1.14 0.13
IFX interaction with calendar period before 2006 2.61 0.70; 9.72 0.15 2.66 0.74; 9.60 0.13
IFX interaction with calendar period 2006–2009 1.15 0.48; 2.74 0.76 0.84 0.38; 1.83 0.66
ADA interaction with calendar period 2006–2009 1.29 0.62; 2.70 0.50 1.18 0.59; 2.35 0.64
Multivariable adjusted Cox regression models with complete case data for treatment retention (A) and time up to dose escalation/stop (B) in axSpA patients treated with
a first TNFi. ETA and the period after 2009 are used as references in this model. A total of 347 patients are analyzed. HRs >1 indicate increased hazard for
discontinuation. ADA = adalimumab, AS = ankylosing spondylitis, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, BASFI = Bath Ankylosing
Spondylitis Functional Index, BMI = body mass index, CI = confidence interval, CRP = C-reactive protein, csDMARD = conventional synthetic disease-modifying anti-
rheumatic drug, ETA = etanercept, GOL = golimumab, HLA-B27 = Human Leucocyte Antigen B27, HR = hazard ratio, IFX = infliximab, nr-axSpA = nonradiographic
axial spondyloarthritis, TNFi = Tumor Necrosis Factor inhibitor.
https://doi.org/10.1371/journal.pone.0216746.t003
Table 4. Comparison of drug survival as well as drug survival up to dose escalation between different anti-TNF agents, stratified by the period of treatment initia-
tion, in respective multiple adjusted cox regression models.
Calendar period Before 2006 2006–2009 After 2009
Available TNFi ETA / IFX ADA / ETA /IFX ADA / ETA / GOL / IFX
A. Drug survival HR 95% CI P HR 95% CI P HR 95% CI P
IFX vs. ETA 3.10 1.52; 6.33 0.002 0.78 0.50; 1.21 0.27 0.89 0.59; 1.33 0.57
ADA vs. ETA 0.84 0.58; 1.23 0.37 0.98 0.71; 1.35 0.90
GOL vs. ETA 0.79 0.55; 1.11 0.17
B. Drug survival up to dose escalation HR 95% CI P HR 95% CI P HR 95% CI P
IFX vs. ETA 2.58 1.30 ; 5.10 0.007 1.00 0.67; 1.49 0.99 1.16 0.80; 1.67 0.44
ADA vs. ETA 0.85 0.59; 1.21 0.37 0.93 0.69; 1.26 0.66
GOL vs. ETA 0.80 0.58; 1.10 0.17
A. Summarized data for differences in retention rates between individual TNFi calculated from cox regression model in Fig 2. HRs>1 indicate increased hazard to
discontinue first TNFi. B. Summarized data for differences in drug maintenance up to dose escalation from model in Table 3. ADA = adalimumab, CI = confidence
interval, ETA = etanercept, GOL = golimumab, HR = hazard ratio, IFX = infliximab, TNFi = Tumor Necrosis Factor inhibitor. The analyses were adjusted for
comedication with coventional synthetic disease-modifying anti-rheumatic drugs, calendar period of treatment, disease duration, sex, classification status as
nonradiographic axial spondyloarthritis versus ankylosing spondylitis, elevated C-reactive protein status, Bath Ankylosing Spondylitis Disease Activity Index, current
smoking and education.
https://doi.org/10.1371/journal.pone.0216746.t004
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dose escalation/stop for IFX versus ETA, but only for the calendar period before 2006
(Table 4B). The model yielded similar retention rates up to dose escalation for all TNFi, when
treatment was initiated after 2006 (Table 4B).
Discussion
Drug retention was compared between ADA, ETA, GOL and IFX in patients with axSpA start-
ing their first TNFi after inclusion into the SCQM axSpA cohort. Retention was comparable
when treatment was initiated after 2009, when all four agents were available for treatment. A
significant difference in discontinuation rate was only found in patients who started treatment
before 2006, when only ETA and IFX were approved for this indication in Switzerland,
although this observation is based on a rather limited number of patients, as the cohort had
been initiated late in 2004. We have only considered IFX treatments with the registered stan-
dard dose of 5 mg/kg every 8 weeks, eliminating the possibility that the shorter drug survival
on IFX during this calendar period might be due to the usage of the lower dose registered for
rheumatoid arthritis. While in psoriatic arthritis a lower starting dose did not affect drug sur-
vival or response in Icelandic and Danish patients [19], this issue has not been sufficiently
investigated in axSpA to date. Whether a differential potential of immunogenicity [20] might
explain the differences in drug survival between ETA and IFX before 2006 remains unclear, as
serum samples to assess the presence of anti-drug antibodies were not available and a causal
association would still be difficult to demonstrate [21]. The observation that a higher propor-
tion of patients treated with IFX were co-treated with a csDMARD, might have levelled poten-
tial differences in the longer term [2, 8]. The finding that comedication with csDMARDs did
not significantly affect drug retention of TNFi is in line with current international axSpA treat-
ment recommendations [22]. Our study confirms the importance of adjusting drug survival
analyses for the year or period of treatment initiation [11]. Drug survival on ETA and on ADA
decreased over time, paralleling the increasing number of available anti-TNF treatment
options, corroborating findings in rheumatoid arthritis [11]. In contrast, a longer drug
Fig 3. Kaplan-Meier curve showing drug maintenance of the first TNFi up to dose escalation, stratified by the
type of TNFi used. ADA = adalimumab, ETA = etanercept, GOL = golimumab, IFX = infliximab.
https://doi.org/10.1371/journal.pone.0216746.g003
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maintenance on IFX was observed for treatments initiated in the period 2006–2009, compared
to treatments started before 2006. The reason for this finding remains unknown, but might
involve channeling of particular patients to treatment with IFX and accordingly more regular
clinical visits, in contrast to treatment with subcutaneously self-administered anti-TNF agents.
Channeling might have also involved patients with extra-articular manifestations, as mirrored
in the differences observed in the baseline characteristics. The antagonistic course of drug
maintenance over time for IFX versus other anti-TNF agents contributed to the alignment of
drug retention rates in later time periods. Drug retention rates were also comparable between
the TNFi inhibitors during these periods after accounting for differences in the proportion of
patients with dose escalation in the multiple adjusted analysis. The unadjusted analysis had, in
contrast, revealed a significantly lower time to drug escalation/stop for IFX versus ETA over
the whole follow-up in SCQM.
The main predictors of enhanced drug survival in our analysis were male versus female sex,
classification as AS versus nr-axSpA, elevated baseline CRP levels as well as vocational versus
compulsory education. We acknowledge the fact that residual confounding in the context of
this observational study may still exist. Our analysis points to changes in the axSpA population
starting a first TNFi over time, as patients initiating GOL, licensed in 2010, had a significantly
lower disease activity and a better spinal mobility and function. Only a minority of patients ini-
tiated CER since its registration for axSpA in 2013, indicating that it is mainly used as a sec-
ond-line TNFi in Switzerland. This precluded the inclusion of CER in the comparison of drug
survival of different TNFi.
Conclusion
Time to treatment discontinuation and time to dose escalation/stop were both comparable for
ADA, ETA, GOL and IFX in adjusted analyses in the period of time when all four anti-TNF
agents were available on the market.
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